Education
About Us
Working with TipRanks
Follow Us
Spruce Biosciences (SPRB)
NASDAQ:SPRB
RESEARCH TOOLSreports
SPRB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.34 - $5.95
Previous CloseN/A
Volume285.87K
Average Volume (3M)360.51K
Market Cap
$16.07M
Enterprise Value-$37.21M
Total Cash (Recent Filing)-$4.11M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Mar 12, 2025EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.96
Shares Outstanding41,302,600
10 Day Avg. Volume388,999
30 Day Avg. Volume360,515
Standard Deviation0.38
R-Squared0.09
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.27
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market Cap-2.32
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.95
Enterprise Value/Ebitda0.95
Forecast
1Y Price Target
$1.25Price Target Upside220.51% Upside
Rating ConsensusHold
Number of Analyst Covering5
---
Spruce Biosciences News
PremiumCompany Announcements
Spruce Biosciences Appoints Interim Chief Medical Officer
---
Bulls Say, Bears Say
Bulls Say
Financial StabilitySpruce Biosciences ended 3Q24 with $60.1M in cash and cash equivalents, which is expected to be sufficient to fund operations at least into 2026.
Strategic PartnershipsSpruce Biosciences entered a low-risk partnership with HMNC Brain Health to run a Phase 2 proof-of-concept trial of tildacerfont in major depressive disorder.
Bears Say
Clinical Trial ResultsTildacerfont missed the primary endpoint of an absolute change in daily glucocorticoid dose after 24 weeks vs. placebo.
---
Ownership Overview
19.78% Insiders
2.69% Mutual Funds
19.52% Other Institutional Investors
55.99% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SPRB FAQ
What was Spruce Biosciences’s price range in the past 12 months?
Spruce Biosciences lowest stock price was $0.34 and its highest was $5.95 in the past 12 months.
What is Spruce Biosciences’s market cap?
Spruce Biosciences’s market cap is $16.07M.
When is Spruce Biosciences’s upcoming earnings report date?
Spruce Biosciences’s upcoming earnings report date is Mar 12, 2025 which is in 8 days.
How were Spruce Biosciences’s earnings last quarter?
Spruce Biosciences released its earnings results on Nov 11, 2024. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.238 by $0.028.
Is Spruce Biosciences overvalued?
According to Wall Street analysts Spruce Biosciences’s price is currently Undervalued.
Does Spruce Biosciences pay dividends?
Spruce Biosciences does not currently pay dividends.
What is Spruce Biosciences’s EPS estimate?
Spruce Biosciences’s EPS estimate is -0.21.
How many shares outstanding does Spruce Biosciences have?
Spruce Biosciences has 41,302,600 shares outstanding.
What happened to Spruce Biosciences’s price movement after its last earnings report?
Spruce Biosciences reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.238. Following the earnings report the stock price went down -1.852%.
Which hedge fund is a major shareholder of Spruce Biosciences?
Among the largest hedge funds holding Spruce Biosciences’s share is Aisling Capital Management LP. It holds Spruce Biosciences’s shares valued at 0.
---
Company Description
Spruce Biosciences
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders. The company is developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).
---
SPRB Stock 12 Month Forecast
Average Price Target
$1.25
▲(220.51% Upside)
Technical Analysis
---